according to GB/T 16483 and GB/T 17519



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

#### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Montelukast Granules Formulation

### Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone : +1-551-430-6000

Emergency telephone number: +1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

#### 2. HAZARDS IDENTIFICATION

#### **Emergency Overview**

**Appearance** : powder

Colour: No data availableOdour: No data available

Not a hazardous substance or mixture.

#### **GHS Classification**

Not a hazardous substance or mixture.

#### **GHS** label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

### Physical and chemical hazards

Not classified based on available information.

### **Health hazards**

Not classified based on available information.

#### **Environmental hazards**

Not classified based on available information.

according to GB/T 16483 and GB/T 17519



## **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

#### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

#### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Montelukast	151767-02-1	>= 0.1 -< 1

#### 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

Notes to physician

delayed

Contact with dust can cause mechanical irritation or drying of

the skin.

Protection of first-aiders

Dust contact with the eyes can lead to mechanical irritation.

No special precautions are necessary for first aid responders.

Treat symptomatically and supportively.

### 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Specific extinguishing meth-

shing meth- : Use extinguishing measures that are appropriate to local cir-

according to GB/T 16483 and GB/T 17519



## **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

ods cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary

Use personal protective equipment.

### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 7. HANDLING AND STORAGE

Handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation.

Do not breathe dust.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use.

according to GB/T 16483 and GB/T 17519



### **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

Avoidance of contact : Oxidizing agents

Storage

Conditions for safe storage : Keep in properly labelled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

#### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
•		(Form of	ters / Permissible	
		exposure)	concentration	
Montelukast	151767-02-1	TWA	40 μg/m3 (OEB 3)	Internal
		Wipe limit	400 μg/100 cm <sup>2</sup>	Internal

**Engineering measures** : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

tainment devices).

Minimize open handling.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hand protection

according to GB/T 16483 and GB/T 17519



### **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

according to GB/T 16483 and GB/T 17519



## **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

### 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

products

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials

Hazardous decomposition

Oxidizing agents

No hazardous decomposition products are known.

### 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

**Acute toxicity** 

Not classified based on available information.

according to GB/T 16483 and GB/T 17519



## **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

### **Components:**

Montelukast:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 5,000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Skin corrosion/irritation

Not classified based on available information.

**Components:** 

Montelukast:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

**Components:** 

Montelukast:

Species : Rabbit

Result : Severe irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

**Components:** 

Montelukast:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

**Product:** 

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

according to GB/T 16483 and GB/T 17519



### **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

Test system: Chinese hamster fibroblasts

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: negative

Test Type: Alkaline elution assay Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: Mouse

Cell type: Bone marrow Application Route: Oral Result: negative

### **Components:**

Montelukast:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster fibroblasts

Result: negative

Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells

Result: negative

Test Type: Alkaline elution assay Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: Mouse

Cell type: Bone marrow Application Route: Oral

Result: negative

# Carcinogenicity

Not classified based on available information.

**Product:** 

Species : Rat
Application Route : Oral
Exposure time : 2 Years

Dose : 200 mg/kg body weight

Result : negative

according to GB/T 16483 and GB/T 17519



## **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

Species : Mouse
Application Route : Oral
Exposure time : 92 weeks

Dose : 100 mg/kg body weight

Result : negative

#### Components:

### Montelukast:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 92 weeks
Result : negative

### Reproductive toxicity

Not classified based on available information.

#### **Product:**

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral

Fertility: NOAEL Parent: 800 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: LOAEL Parent: 200 mg/kg body weight

Symptoms: Reduced fertility

### **Components:**

#### Montelukast:

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral

Fertility: NOAEL: 800 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: LOAEL: 200 mg/kg body weight

Symptoms: Reduced fertility

according to GB/T 16483 and GB/T 17519



## **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: NOAEL: 100 mg/kg body weight

Symptoms: Reduced fertility

## STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### **Components:**

## Montelukast:

Species : Monkey, male and female

NOAEL : 150 - 300 mg/kg

Application Route : Oral Exposure time : 53 Weeks

Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Remarks : No significant adverse effects were reported

### **Aspiration toxicity**

Not classified based on available information.

## Experience with human exposure

#### **Product:**

Skin contact : Remarks: May irritate skin. Eye contact : Symptoms: Severe irritation

Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,

Headache, Cough, Abdominal pain, Diarrhoea, Fever

### **Components:**

### Montelukast:

Skin contact : Remarks: May irritate skin. Eye contact : Symptoms: Severe irritation

according to GB/T 16483 and GB/T 17519



## **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,

Headache, Cough, Abdominal pain, Diarrhoea, Fever

#### 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

#### **Components:**

Montelukast:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

NOEC (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.073 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility

NOEC (Cyprinodon variegatus (sheepshead minnow)): 0.0816

mg/l

Exposure time: 7 d

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.23 mg/l

Exposure time: 21 d

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50: > 100 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

according to GB/T 16483 and GB/T 17519



## **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

### Persistence and degradability

### **Components:**

Montelukast:

Biodegradability : Result: not rapidly degradable

Biodegradation: 0 % Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(21.7 h)

### Bioaccumulative potential

### **Components:**

Montelukast:

Partition coefficient: n-

octanol/water

log Pow: > 4.3

Mobility in soil
No data available

Other adverse effects

No data available

#### 13. DISPOSAL CONSIDERATIONS

**Disposal methods** 

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### 14. TRANSPORT INFORMATION

### International Regulations

**UNRTDG** 

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable Proper shipping name : Not applicable

according to GB/T 16483 and GB/T 17519



### **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen- : Not applicable

ger aircraft)

**IMDG-Code** 

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable

Marine pollutant : no

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### **National Regulations**

GB 6944/12268

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Marine pollutant : no

Special precautions for user

Not applicable

#### 15. REGULATORY INFORMATION

#### **National regulatory information**

Law on the Prevention and Control of Occupational Diseases

**Regulation on the Administration of Precursor Chemicals** 

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

according to GB/T 16483 and GB/T 17519



## **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

IECSC : not determined

#### **16. OTHER INFORMATION**

Revision Date : 2024/04/06

**Further information** 

Sources of key data used to compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : yyyy/mm/dd

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

### **Disclaimer**

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for

according to GB/T 16483 and GB/T 17519



# **Montelukast Granules Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/26 3.2 2024/04/06 22993-00024 Date of first issue: 2014/10/17

safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN